Insulet Corporation (PODD) — ESG & Values Scores

Environment story

Insulet shows moderate environmental performance with no disclosed Scope 1, 2, or 3 emissions data and no published net-zero target, triggering material deductions. The company operates manufacturing facilities in the U.S., Malaysia, and China, and sources components globally, but provides no transparency on supply-chain carbon footprint or renewable energy adoption. No reported controversies involving toxic waste, water depletion, or habitat damage. The company's medical device nature (insulin delivery systems with disposable pods) creates inherent product-usage emissions through logistics and waste, but no Scope 3 quantification or mitigation strategy is disclosed. No identified greenwashing markers (offset-reliance or supply-chain obscuration) as data is simply undisclosed rather than manipulated.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Manufacturing Expansion in Malaysia and Costa Rica

Company began production at new Malaysia facility in 2024 and is investing in Costa Rica manufacturing plant to support growth; no explicit decarbonization or renewable energy integration disclosed.

Social story

Insulet demonstrates mixed social performance. CEO-to-median-worker pay ratio is not disclosed, preventing direct assessment; company experienced leadership transitions in 2025 (new CEO and CFO) with severance costs of $9.3M, but no documented retention crisis. No documented union-suppression activities, major strikes, or NLRB complaints within 24 months. Leadership diversity metrics are not disclosed (no stated % women/URG in executive/board roles), limiting quantitative assessment; board composition shows 9 directors with limited visible gender/ethnic diversity detail in proxy summary. Supply-chain ethics undisclosed—no published conflict minerals, forced-labor, or cobalt/lithium audit disclosures for product components (e.g., battery/sensor supply). Headcount expanded significantly to support business growth but turnover rate not disclosed. No evidence of anti-union sentiment or labor rights violations.

Criticisms on file

Leadership Transition Costs (2025): CEO and CFO departures with severance totaling $9.3M; $11.7M reversal of stock-based compensation for former executives, indicating potential management integration challenges during rapid growth phase.
Source: PODD_10k.txt (MD&A, Adjusted EBITDA reconciliation); PODD_proxy.txt (Board composition notes change in leadership roles in 2025)

Disclosed initiatives

Workforce Expansion and Training

Company added significant headcount in 2025 across commercial, customer experience, and support teams to support 31% revenue growth; invested in training and development for global sales teams.
Direct-to-Consumer and Patient Engagement Programs

Launched DTC advertising, pharmacy channel access, and diabetes educator support infrastructure; emphasis on customer service quality and retention.

Governance story

Insulet demonstrates strong governance with independent board chair, board independence above 75%, no dual-class share structure, and robust shareholder engagement practices. Board refreshment active (4 new directors added since 2024, representing 44% of current 9-member board). No documented antitrust proceedings, consumer-safety fines, or financial-fraud SEC actions. Company discloses no lobbying expenditures targeting climate-regulation weakening or consumer-protection rollbacks. Board committees (Audit, Compensation, Governance, Science & Technology) are fully independent. Annual board self-evaluations and shareholder proxy-access bylaws in place. Majority-voting policy for uncontested director elections enforced. Risks disclosed include reliance on third-party manufacturers (China contract manufacturer and Malaysia facility), supply-chain vulnerabilities, and international regulatory compliance complexity, but no governance failures flagged. One material legal controversy: EOFlow trade-secret misappropriation judgment ($59.4M awarded after reduction; appeal pending and realizability uncertain; not recognized in financial statements per Note 16).

Criticisms on file

EOFlow Co., Ltd. Trade Secret Misappropriation Lawsuit (Settled December 2024): Jury awarded Insulet $452M in damages; court upheld verdict and issued permanent worldwide injunction. Court subsequently reduced monetary award to $59.4M to avoid double recovery due to scope of injunction. EOFlow has appealed; damages award not recognized in consolidated statements pending appeal outcome and realizability assessment.
Source: PODD_10k.txt (Item 7, MD&A, Legal Proceedings; Note 16 to consolidated financial statements)

Disclosed initiatives

Independent Board Leadership and Oversight

Board Chair is independent (Elizabeth H. Weatherman, Special Limited Partner at Warburg Pincus); all four board committees are fully independent (Audit, Compensation, Governance, Science & Technology); regular executive sessions of independent directors held.

Strengthens board independence and insulates decision-making from management influence
Board Refreshment and Diverse Expertise

Added 4 new directors since 2024 (Robert L. Huffines, Ashley A. McEvoy as CEO, Timothy C. Stonesifer, and one other); directors include seasoned leaders from medical devices, finance, healthcare, technology, and academia; varied tenure (1 to 11 years).

Ensures continuous flow of new perspectives and reduces entrenchment risk
Shareholder Engagement and Proxy Access

Proactive year-round shareholder outreach on governance, compensation, and strategy; proxy access bylaw enabling 3%+ shareholders (3-year hold) to nominate up to 20% of directors; no poison pill.

Enhances shareholder voice and reduces agency costs
Executive and Director Stock Ownership Guidelines and Anti-Hedging Policy

Robust stock ownership requirements for executives and directors; no hedging or pledging of securities permitted; clawback/recoupment policy for incentive compensation in place.

Aligns executive compensation with shareholder interests and prevents speculation

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Insulet Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Insulet Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)